MarcDrorMichaelsonMD

Oncology • Boston, MA

Clinical Director, Genitourinary Cancer Center, Massachusetts General Hospital; Associate Professor of Medicine

Join to view full profile

Dr. Michaelson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Michaelson's full profile

Already have an account?

Office
55 Fruit St
Cox 640 Hematology Oncology
Boston, MA 02114
Phone+1 617-726-5187

Fax+1 617-724-3166

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
Albert Einstein College of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 1999 - 2026
NH State Medical License 2021 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
Completed
Phase 1, Phase 2
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2007 Dec 01
Completed
Phase 2
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma Start of enrollment: 2009 Sep 01
Withdrawn
Phase 2
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 3
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu
Journal of Clinical Oncology. 2024-12-01
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTO...
Zaker Rana, Sophia C Kamran, Amol C Shetty, Philip Sutera, Yang Song
European Urology Oncology. 2024-10-01